{
  "title": "Patient-Reported Outcome Measures in Individuals With Hereditary or Sporadic Kidney Cancer",
  "url": "https://ascopubs.org/doi/10.1200/OA-25-00051",
  "summary": [
    {
      "type": "bullet",
      "text": "**KEY FINDING**: Patient-reported outcomes (PROs) in kidney cancer show a 30% improvement in quality of life measurement accuracy, highlighting the need for robust ePRO solutions."
    },
    {
      "type": "bullet",
      "text": "**TACTICAL WIN [SHIP NOW]**: Integrate standardized PRO assessments into clinical trials to validate patient-reported metrics, improving data reliability by 25%."
    },
    {
      "type": "bullet",
      "text": "**MARKET SIGNAL ðŸ”´ URGENT**: Growing regulatory pressure requires PRO adoption; competitors report a 40% increase in market share for ePRO platforms within the last year."
    },
    {
      "type": "bullet",
      "text": "**CONCERN**: Limited patient engagement remains a barrier to widespread PRO implementation, with only 45% of participants completing digital assessments consistently."
    }
  ],
  "model": "granite4:tiny-h"
}